Six presentations demonstrate Galapagos' commitment to the inflammatory bowel disease (IBD) communityNew analyses from Phase 3 SELECTION and SELECTION long-term extension (LTE) studies of Jyseleca® (filgotinib
Investegate announcements from Galapagos NV, Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023
Investegate announcements from Galapagos NV, Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022
Investegate announcements from Galapagos NV, Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress